|
|
|
|
|
||||||||||||||||||||
|
|
Increased adoption of oncology-relevant endpoints beyond overall survival in HTA body / payer decision-making can help to provide timely access to medicines, ensure optimal outcomes for patients and potentially reduce healthcare costs. |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|||
|
||||
|
EFPIA 2026 All rights reserved ·
Disclaimer
·
|